Revenue Recognition - Narrative (Details) - USD ($)			1 Months Ended	3 Months Ended								12 Months Ended			96 Months Ended
	Jul. 06, 2021	May 05, 2020	Jan. 31, 2015	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Prior period performance obligation revenue recognized												$ 21,500,000	$ 40,400,000	$ 300,000
Overpayment reimbursement liability				$ 1,800,000				$ 5,000,000				1,800,000	5,000,000		$ 1,800,000
Revenue recognized												328,000
Total revenues				$ 185,340,000	$ 179,744,000	$ 309,893,000	$ 329,219,000	$ 401,332,000	$ 385,813,000	$ 442,408,000	$ 545,165,000	1,004,196,000	1,774,718,000	1,435,413,000
Pfizer | Products
Disaggregation of Revenue [Line Items]
Revenue recognized															$ 85,000,000
Maximum milestone payments			$ 275,000,000			$ 85,000,000
Initial upfront payment			$ 295,000,000
Nicoya
Disaggregation of Revenue [Line Items]
Initial upfront payment													5,000,000
Rayaldee
Disaggregation of Revenue [Line Items]
Revenue recognized												27,300,000	27,000,000	36,800,000
Total revenues												59,557,000	64,301,000	88,187,000
Revenue from transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues												105,721,000	25,842,000	53,219,000
Revenue from transfer of intellectual property and other | Products
Disaggregation of Revenue [Line Items]
Total revenues		$ 3,000,000
Maximum milestone payments														3,000,000
Revenue from transfer of intellectual property and other | Pfizer | Products
Disaggregation of Revenue [Line Items]
Total revenues												9,300,000	10,800,000	28,700,000
Maximum milestone payments												85,000,000
Revenue from transfer of intellectual property and other | VFMCRP | Products
Disaggregation of Revenue [Line Items]
Total revenues												3,000,000
Revenue from transfer of intellectual property and other | Nicoya | Products
Disaggregation of Revenue [Line Items]
Total revenues												$ 2,500,000
Revenue from transfer of intellectual property and other | LeaderMed | Products
Disaggregation of Revenue [Line Items]
Total revenues													1,000,000
Revenue from transfer of intellectual property and other | CAMP4
Disaggregation of Revenue [Line Items]
Total revenues	$ 1,500,000
Revenue from transfer of intellectual property and other | CAMP4 | Products
Disaggregation of Revenue [Line Items]
Total revenues													$ 4,900,000
Revenue from transfer of intellectual property and other | BioReference Laboratories, Inc. | Products
Disaggregation of Revenue [Line Items]
Total revenues														$ 16,200,000